GHK-Cu and skin rejuvenation

Facial creams and collagen

The most useful place to start is a result that sounds smaller when described accurately. A 2025 review of topical GHK reports increased procollagen synthesis in 70% of GHK-Cu-treated subjects, compared with 50% for vitamin C and 40% for retinoic acid. Those percentages describe the subjects showing an increase. They do not say that everyone produced 70% more collagen.

The 2015 skin-regeneration review also describes placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density. These are small topical studies. I’m encouraged by outcomes that name an actual feature of skin; I’m far less persuaded when the same findings acquire a claim about rejuvenating the entire body.

Collagen turnover

GHK-Cu consists of glycine, histidine and lysine bound to copper(II). The same GHK sequence occurs in collagen and SPARC/osteonectin, as described in the review of GHK’s structure and repair biology. A fibroblast is a connective-tissue cell that makes collagen and other supporting material; these are the cells behind much of the early work.

In the 1988 human fibroblast-culture experiment, collagen synthesis increased without a change in cell number. Stimulation began between 10^-12 and 10^-11 M and maximised at 10^-9 M. I admire this narrow result: it pins down a metabolic response in those cultured cells.

The 2008 review of tissue remodelling describes synthesis of collagen and elastin alongside changes in metalloproteinases and their inhibitors, which help regulate matrix breakdown. Repair involves turnover as well as production. Copper also participates in the cross-linking of collagen and elastin. This busy local biology gives “renewal” some substance, while the human whole-body question remains unanswered.

GHK-Cu skin delivery

A cream has a practical obstacle between its ingredient list and the cells below: the outer skin barrier. The topical-delivery review gives free GHK a cLogP of -2.24, indicating its strong preference for watery surroundings and poor passive passage through intact skin. It discusses palmitoylation, liposomes and microneedle pretreatment as delivery approaches, with early evidence that depends on the particular preparation.

There is also a skin-layer experiment measuring copper penetration. It used excised human skin, outside a living person. In dermatomed skin, the reported permeability coefficient was 2.43 +/- 0.51 x 10^-4 cm/h; over 48 hours, 136.2 +/- 17.5 ug/cm^2 of copper permeated and 97 +/- 6.6 ug/cm^2 remained as a dermal depot. Those are copper measurements. They describe passage and retention under the experimental conditions.

I’d assess a new formulation on its own delivery data. A copper depot in excised skin leaves clinical benefit, the intact peptide’s fate and systemic safety as further questions.

GHK and age-related claims

The reported decline in plasma GHK—from about 200 ng/mL at age 20 to about 80 ng/mL by age 60—appears in the skin-regeneration review. It invites an obvious hypothesis about ageing. Testing that hypothesis in humans would require evidence about exposure and meaningful outcomes after systemic administration, which the current record lacks.

The 2018 review of gene-expression data reports that GHK altered expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, with 59% of affected genes upregulated and 41% downregulated. Its protein quality-control tally includes 41 genes up and 1 down. These are database and laboratory findings, with protein-level and in-vivo validation still needed. The familiar “~4,000 genes” figure is an extrapolation; the 50% threshold table covers on the order of 2,100 genes.

I’m unconvinced by calling a broad gene signature a rejuvenation outcome. The number of genes affected says little by itself about whether a person’s health or function improves. Much of the foundational work and the reviews also comes from Pickart and colleagues, leaving wider replication especially valuable.

GHK-Cu irritation and safety

Topical copper-peptide cosmetics have a long history of use. Community accounts describe firmer-feeling skin, softer-looking lines and improved hydration, as well as irritation, redness, itching, dryness and occasional breakouts. Pigment accounts run in both directions: some people describe faded marks, others darker or patchier spots. These are anecdotal accounts, not clinical evidence, and they cannot establish how often an effect occurs.

The review of topical GHK and formulation problems is the starting point for the clinical and delivery cautions. Strong reducing agents such as ascorbic acid and low-pH actives can disrupt the copper complex; formulation compatibility matters. Injectable and systemic GHK-Cu have no validated human pharmacokinetic basis. Repeated systemic copper exposure also raises a theoretical copper-accumulation or copper–zinc-balance concern, particularly with copper-handling disorders such as Wilson’s disease. No human copper-toxicity case attributed to GHK-Cu appears in the published record described here.

GHK-Cu has no FDA- or EMA-approved therapeutic indication by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK; injectable GHK-Cu also has a prescription route requiring individual clinical assessment. Research-labelled GHK-Cu remains on sale outside that route. GHK-Cu was not itemised by name in the 2024–2025 WADA lists cited in the research record, although the S0 category can cover non-approved pharmacological substances. That dated description cannot establish an athlete’s current eligibility.

Hair counts in 45 men

The six-month trial in 45 men with androgenetic alopecia tested a topical complex of 5-aminolevulinic acid and GHK. Hair count increased by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05). No adverse events were reported in any group. Those concentrations belong to the studied preparations.

The mixture is crucial to the attribution: the trial tested 5-aminolevulinic acid plus GHK, rather than pure GHK-Cu. I value the hair count as a concrete human outcome. Its result belongs to that preparation, and it supplies no evidence for injected GHK-Cu or for the GLOW blend.

The comparison page follows that attribution problem into GLOW. Adding ingredients also adds questions about what each one contributes.